复发性小细胞肺癌治疗进展  

Advances in the Treatment of Relapsed Small Cell Lung Cancer

作　　者：刘斌[1] 秦建文[1] 周静敏[1] 

机构地区：[1]天津市胸科医院呼吸与危重症科二病区,天津300222

出　　处：《中国肺癌杂志》2017年第3期192-198,共7页Chinese Journal of Lung Cancer

摘　　要：小细胞肺癌(small cell lung cancer,SCLC)是一种高度恶性肿瘤,初始治疗对放化疗均较敏感,缓解率高,但治疗后易发生耐药并复发。虽然近年来肺癌的治疗发生了翻天覆地的变化,但SCLC复发后的治疗依然是临床上棘手的难题。鉴于复发性SCLC对现有化疗药物的耐药性严重,国内外对复发性SCLC的研究多集中在新药物研制、化疗方案优化及靶点药物的开发等临床试验上。本文对近年来复发性SCLC的化疗和精准治疗的各项研究和文献报道进行总结与评价,期望能够对复发性SCLC的临床治疗有所启发,并为复发性SCLC治疗的临床研究指引方向。Small cell lung cancer（SCLC） is a highly malignant tumor. The initial treatment of radiotherapy and chemotherapy are more sensitive,high remission rate,but susceptible to drug resistance and relapse after treatment. Although the treatment of lung cancer has undergone enormous changes in recent years,treatment for relapsed SCLC is still a difficult problem in clinical field. In view of the serious resistance of recurrent SCLC to the existing chemotherapeutic drugs,the research on recurrent SCLC around the world is focused on the clinical trial of new drug development,optimization of chemotherapy regimen and target drug development. This paper summarize and estimate studies and literature reports of chemotherapy and precision therapy for relapsed SCLC,hopefully it could help clinicians treat relapsed SCLC and give us clinical research direction for relapsed SCLC in the future.

关 键 词：肺肿瘤 复发 化疗 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]